Grail (NASDAQ:GRAL - Get Free Report) is expected to issue its quarterly earnings data before the market opens on Tuesday, February 11th. Analysts expect the company to announce earnings of ($4.41) per share for the quarter.
Grail (NASDAQ:GRAL - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($3.94) earnings per share for the quarter. The firm had revenue of $28.65 million for the quarter. On average, analysts expect Grail to post $-65 EPS for the current fiscal year and $-15 EPS for the next fiscal year.
Grail Stock Up 18.4 %
NASDAQ:GRAL traded up $6.11 during mid-day trading on Wednesday, reaching $39.26. 1,777,607 shares of the company's stock traded hands, compared to its average volume of 1,108,809. Grail has a 12-month low of $12.33 and a 12-month high of $39.48. The company has a 50 day moving average price of $22.29 and a 200-day moving average price of $17.43.
Analyst Upgrades and Downgrades
Several brokerages recently issued reports on GRAL. Guggenheim began coverage on shares of Grail in a research report on Thursday, October 17th. They set a "neutral" rating on the stock. Morgan Stanley assumed coverage on Grail in a report on Wednesday, November 27th. They set an "equal weight" rating and a $16.00 target price on the stock. Finally, Wolfe Research assumed coverage on Grail in a research report on Friday, November 15th. They issued a "peer perform" rating for the company.
Read Our Latest Stock Analysis on GRAL
Insider Activity
In related news, CFO Aaron Freidin sold 30,452 shares of the stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $14.02, for a total value of $426,937.04. Following the completion of the transaction, the chief financial officer now directly owns 268,277 shares in the company, valued at $3,761,243.54. This trade represents a 10.19 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Grail Company Profile
(
Get Free Report)
GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.
Further Reading
Before you consider Grail, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grail wasn't on the list.
While Grail currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
